Market is forward looking…
In theory, CYC FDA approval opened the US market to them.
I would say many new investors have a taken a short term position for a quick gain upon approval.
Of course if Sofdra sales are strong in the US, then the share price will rise accordingly. What I mean to say is I can’t picture a massive SP jump on approval.
DXB is a bit different in that the licensing announcement came suddenly, which resulted in a massive jump on the day as investors scrambled to get in…
Just my thoughts, no offence, could be wrong etc
BOT - Anything but charting, page-8835
-
- There are more pages in this discussion • 1,545 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 408524 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |